Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
168 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. · N Engl J Med · 2022Clinical Trial, Phase III, Comparative Study
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P, Szer J, Weitz I, et al. · N Engl J Med · 2021Clinical Trial, Phase III, Comparative Study
- A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
Wright RD, Bannerman F, Beresford MW, et al. · BMC Nephrol · 2020Research Support, Non-U.S. Gov't, Systematic Review
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. · Blood · 2019Clinical Trial, Phase III, Comparative Study
- The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P, Young NS, Schubert J, et al. · N Engl J Med · 2006Clinical Trial, Phase III, Multicenter Study
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG, Hill A, Rottinghaus ST, et al. · Blood · 2019Clinical Trial, Phase III, Comparative Study
- Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.
Kulasekararaj A, Brodsky R, Schrezenmeier H, et al. · Ann Hematol · 2025Clinical Trial, Phase III, Multicenter Study
- Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.
Garred P, Tenner AJ, Mollnes TE · Pharmacol Rev · 2021Systematic Review
- Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
Röth A, He G, Tong H, et al. · Am J Hematol · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
Luznik L, O'Donnell PV, Symons HJ, et al. · Biol Blood Marrow Transplant · 2008Clinical Trial, Multicenter Study
- Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW, Griffin M, Kim JS, et al. · Lancet Haematol · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
Scheinberg P, Clé DV, Kim JS, et al. · Am J Hematol · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.
Risitano AM, Kulasekararaj AG, Scheinberg P, et al. · Lancet Haematol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.
Bodó I, Amine I, Boban A, et al. · Adv Ther · 2023Systematic Review, Research Support, Non-U.S. Gov't
- Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.
Kulasekararaj A, Griffin M, Piatek C, et al. · Blood · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.
de Castro C, Kelly RJ, Griffin M, et al. · Adv Ther · 2025Clinical Trial, Phase III, Multicenter Study
- Paroxysmal nocturnal haemoglobinuria in pregnancy-a systematic review with meta analysis.
Manning JE, Ciantar E, Griffin M, et al. · Ann Hematol · 2025Systematic Review, Meta-Analysis
- Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review.
Jacobs JW, Figueroa Villalba CA, Booth GS, et al. · Blood Adv · 2023Systematic Review
- Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.
Kulasekararaj AG, Lehtinen AE, Forsyth C, et al. · Haematologica · 2024Clinical Trial, Phase II, Letter
- Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ࣙ10 g/dL) who had received eculizumab or were naive to complement inhibitors.
Panse J, Daguindau N, Okuyama S, et al. · PLoS One · 2024Clinical Trial, Phase I, Clinical Trial, Phase III
- Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.
Zhou S, Dong X, Chen C, et al. · J Pediatr Hematol Oncol · 2021Meta-Analysis, Research Support, Non-U.S. Gov't
- Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.
Risitano AM, de Castro C, Han B, et al. · Blood Adv · 2025Clinical Trial, Phase III, Multicenter Study
- Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria.
Sorigue M, Juncà J, Orna E, et al. · J Thromb Thrombolysis · 2017Clinical Trial, Letter
- Modified Ham test for atypical hemolytic uremic syndrome.
Gavriilaki E, Yuan X, Ye Z, et al. · Blood · 2015Clinical Trial, Research Support, Non-U.S. Gov't
- Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis.
Muvaffak E, Mokresh ME, Varda A, et al. · Expert Rev Hematol · 2024Systematic Review, Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.